Added to YB: 2026-09-16
Pitch date: 2026-09-14
DCTH [bullish]
Delcath Systems, Inc.
Author Info
Golden Bear Capital are operators and ex‑CEOs analyzing companies like people who’ve run them, then timing entries with disciplined, technical swing trading. Sign up for the newsletter.
Company Info
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Market Cap
$552.1M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-397.07
P/E
1.1K
EV/Sales
4.81
Sector
Health Care Equipment and Supplies
Category
growth
Wall Street Radar: Stocks to Watch Next Week - Delcath Systems, Inc.
DCTH: Delcath’s first clean quarter after two years of pricing and volume pressure showed 20% revenue growth to $29.1M, 90% gross margin and positive earnings and cash flow; raised guidance implies at least 28% HEPZATO volume growth. Open on a flag break if the 20-day EMA holds and reassess at $17 resistance. Risks include seasonal treatment capacity, weak trial enrollment and only two to three weeks of demand visibility.
Read full article (6 min)